These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 37482525)
1. Factors Influencing Physician Discretion to Administer CNS Prophylaxis in Diffuse Large B Cell Lymphoma: A Single Institution Retrospective Study. Hino C; Lacy C; Brothers J; Cao H; Mirshahidi H; Park K; Akhtari M Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):764-771. PubMed ID: 37482525 [TBL] [Abstract][Full Text] [Related]
2. Model for Predicting Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Discussion of Prophylaxis Measures. Cui JY; Liu YF; Gao B; Mi L; Deng LJ; Zhu J; Hou SL World Neurosurg; 2023 Nov; 179():e387-e396. PubMed ID: 37652134 [TBL] [Abstract][Full Text] [Related]
3. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study. Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700 [TBL] [Abstract][Full Text] [Related]
4. Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse. Akimoto M; Miyazaki T; Takahashi H; Saigusa Y; Takeda T; Hibino Y; Tokunaga M; Ohashi T; Matsumura A; Teshigawara H; Suzuki T; Teranaka H; Nakajima Y; Matsumoto K; Hashimoto C; Fujimaki K; Fujita H; Sakai R; Fujisawa S; Nakajima H Int J Hematol; 2024 Feb; 119(2):164-172. PubMed ID: 38233702 [TBL] [Abstract][Full Text] [Related]
5. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma. Kansara R Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318 [TBL] [Abstract][Full Text] [Related]
6. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. Gleeson M; Counsell N; Cunningham D; Chadwick N; Lawrie A; Hawkes EA; McMillan A; Ardeshna KM; Jack A; Smith P; Mouncey P; Pocock C; Radford JA; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D Ann Oncol; 2017 Oct; 28(10):2511-2516. PubMed ID: 28961838 [TBL] [Abstract][Full Text] [Related]
7. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Wilson MR; Eyre TA; Kirkwood AA; Wong Doo N; Soussain C; Choquet S; Martinez-Calle N; Preston G; Ahearne M; Schorb E; Moles-Moreau MP; Ku M; Rusconi C; Khwaja J; Narkhede M; Lewis KL; Calimeri T; Durot E; Renaud L; Øvlisen AK; McIlroy G; Ebsworth TJ; Elliot J; Santarsieri A; Ricard L; Shah N; Liu Q; Zayac AS; Vassallo F; Lebras L; Roulin L; Lombion N; Manos K; Fernandez R; Hamad N; Lopez-Garcia A; O'Mahony D; Gounder P; Forgeard N; Lees C; Agbetiafa K; Strüßmann T; Htut TW; Clavert A; Scott H; Guidetti A; Barlow BR; Tchernonog E; Smith J; Miall F; Fox CP; Cheah CY; El Galaly TC; Ferreri AJM; Cwynarski K; McKay P Blood; 2022 Apr; 139(16):2499-2511. PubMed ID: 34995350 [TBL] [Abstract][Full Text] [Related]
8. The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis. Lin Z; Chen X; Liu L; Zeng H; Li Z; Xu B Crit Rev Oncol Hematol; 2022 Aug; 176():103756. PubMed ID: 35809794 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis. Tolley ER; Lewinter C; Pedersen LM; Nielsen TH Haematologica; 2024 Oct; 109(10):3327-3337. PubMed ID: 38497149 [TBL] [Abstract][Full Text] [Related]
10. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma. Puckrin R; El Darsa H; Ghosh S; Peters A; Owen C; Stewart D Am J Hematol; 2021 Jul; 96(7):764-771. PubMed ID: 33811794 [TBL] [Abstract][Full Text] [Related]
11. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery. Wilson MR; Eyre TA; Martinez-Calle N; Ahearne M; Parsons KE; Preston G; Khwaja J; Schofield J; Elliot J; Mula Kh A; Shah N; Cheung CK; Timmins MA; Creasey T; Linton K; Smith J; Fox CP; Miall F; Cwynarski K; McKay P Blood Adv; 2020 Aug; 4(15):3586-3593. PubMed ID: 32761231 [TBL] [Abstract][Full Text] [Related]
12. [Risk assessment and prophylactic treatment strategies for central nervous system relapse of diffuse large B-cell lymphoma]. Miyazaki K Rinsho Ketsueki; 2023; 64(6):490-496. PubMed ID: 37407473 [TBL] [Abstract][Full Text] [Related]
13. Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. Bobillo S; Joffe E; Sermer D; Mondello P; Ghione P; Caron PC; Hamilton A; Hamlin PA; Horwitz SM; Kumar A; Matasar MJ; Batlevi CL; Moskowitz A; Noy A; Owens CN; Palomba ML; Straus D; von Keudell G; Dogan A; Zelenetz AD; Seshan VE; Younes A Blood Cancer J; 2021 Jun; 11(6):113. PubMed ID: 34135307 [TBL] [Abstract][Full Text] [Related]
14. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis. Fang Y; Su N; Ma S; Cai J; Zhong L; Li W; Huang H; Li Z; Huang H; Xia Y; Liu P; Guo L; Li Z; Wu Y; Tian X; Wang J; Zhang Y; Cai Q Ann Hematol; 2022 Mar; 101(3):595-605. PubMed ID: 34985557 [TBL] [Abstract][Full Text] [Related]
15. Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity. Eyre TA; Kirkwood AA; Wolf J; Hildyard C; Mercer C; Plaschkes H; Griffith J; Fields P; Gunawan A; Oliver R; Booth S; Martinez-Calle N; McMillan A; Bishton M; Fox CP; Collins GP; Hatton CSR Br J Haematol; 2019 Oct; 187(2):185-194. PubMed ID: 31222719 [TBL] [Abstract][Full Text] [Related]
16. Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era. Zhang N; Xu D; Liu B; Shi X; Xie X; Wang Z Int Immunopharmacol; 2022 Dec; 113(Pt A):109299. PubMed ID: 36252471 [TBL] [Abstract][Full Text] [Related]
17. Patient selection and tolerability of high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma. Garwood MJ; Hawkes EA; Churilov L; Chong G Cancer Chemother Pharmacol; 2020 Jan; 85(1):133-140. PubMed ID: 31848681 [TBL] [Abstract][Full Text] [Related]
18. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Arkenau HT; Chong G; Cunningham D; Watkins D; Agarwal R; Sirohi B; Trumper M; Norman A; Wotherspoon A; Horwich A Ann Oncol; 2007 Mar; 18(3):541-5. PubMed ID: 17164228 [TBL] [Abstract][Full Text] [Related]
19. Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of intravenous high-dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis. Bennett R; Ruskova A; Coomarasamy C; Theakston E; Berkahn L; Jackson S; Christophers M; Wong S; Issa S Am J Hematol; 2023 Jul; 98(7):1070-1079. PubMed ID: 37161765 [TBL] [Abstract][Full Text] [Related]
20. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]